FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386989205> ?p ?o ?g. }

• W4386989205 endingPage "e22" @default.
• W4386989205 startingPage "e22" @default.
• W4386989205 abstract "Abstract Background PVZ remains the only licensed intervention to prevent severe RSV infection. The last formal cost-utility analysis (CUA) of its use in Canadian premature infants was published in 2010 (Smart J Med Econ 2010). Since then, the 3-variable International Risk Scoring tool (IRST) has been published (Blanken Pediatr Pulmonol 2018), which can guide prophylaxis for infants born 32-35 wGA at greatest risk of RSV hospitalization (RSVH). Objectives The objective of this study was to incorporate the IRST and non-hospitalized, medically-attended (emergency room/outpatient) RSV infections (MARI) into a CUA for the first time to provide an up-to-date economic evaluation of palivizumab versus no prophylaxis in Canadian 29-31 wGA and 32-35 wGA infants. Design/Methods Infants followed a semi-Markov process, having an RSVH, MARI, or being uninfected/non-medically attended. Hospitalized infants could be admitted to the intensive care unit (ICU; 17.9%) and ICU-admitted infants could die (0.43%). All surviving infants could experience respiratory morbidity up to 18 years, according to RSV infection and PVZ status. The RSVH rate in non-prophylaxed 29-31 wGA and moderate to high (MH) risk 32-35 wGA infants was 5.9% and 6.3%, respectively. PVZ reduced RSVH by 63.3% and 82.2% in 29-31 wGA and 32-35 wGA infants, respectively. PVZ costs (assuming 50 mg: CAN$752; 100 mg: $1,505) were calculated using Canadian birth statistics. The base case assumed all 29-31 wGA infants and MH-risk 32-35 wGA infants received PVZ, inclusion of indirect costs, no vial sharing, and a lifetime time horizon with 1.5% discounting. A cost per quality-adjusted life-year (QALY) of ≤$50,000 was considered cost-effective. Results PVZ prophylaxis resulted in a cost/QALY of $29,579 in 29-31 wGA infants and $27,951 in MH-risk 32-35 wGA infants versus no prophylaxis. In deterministic sensitivity analyses (±20% on main variables) the model was most sensitive to utility scores, PVZ cost, non-prophylaxed RSVH rate, and PVZ efficacy. Probabilistic sensitivity analyses (10,000 iterations) resulted in incremental costs of $30,857/QALY, with a 76.0% probability of cost-effectiveness at a $50,000 willingness-to-pay threshold for 29-31 wGA infants, and $28,167/QALY and 79.1% for MH-risk 32-35 wGA infants. Conclusion This new CUA, the first to incorporate the IRST and MARI, found that PVZ is highly cost-effective in Canadian 29-35 wGA infants (vs no prophylaxis) and has implications for prophylaxis policies in Canada. Potential competing interests Xavier Carbonell-Estrany and Bosco Paes have received research funding and/or compensation as advisor/lecturer from AbbVie and AstraZeneca. Jean-Eric Tarride has nothing to disclose. Barry Rodgers-Gray, Ian Keary and John Fullarton employers have received payment from AbbVie and AstraZeneca for work on various projects." @default.
• W4386989205 created "2023-09-24" @default.
• W4386989205 creator A5005722406 @default.
• W4386989205 creator A5041366453 @default.
• W4386989205 creator A5049220408 @default.
• W4386989205 creator A5061381877 @default.
• W4386989205 creator A5065291663 @default.
• W4386989205 creator A5068857043 @default.
• W4386989205 date "2023-09-01" @default.
• W4386989205 modified "2023-10-18" @default.
• W4386989205 title "50 New Analysis on the Cost-effectiveness of Palivizumab (PVZ) for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Canadian Infants Born 29-31 and 32-35 weeks’ Gestational Age (wGA)" @default.
• W4386989205 doi "https://doi.org/10.1093/pch/pxad055.050" @default.
• W4386989205 hasPublicationYear "2023" @default.
• W4386989205 type Work @default.
• W4386989205 citedByCount "0" @default.
• W4386989205 crossrefType "journal-article" @default.
• W4386989205 hasAuthorship W4386989205A5005722406 @default.
• W4386989205 hasAuthorship W4386989205A5041366453 @default.
• W4386989205 hasAuthorship W4386989205A5049220408 @default.
• W4386989205 hasAuthorship W4386989205A5061381877 @default.
• W4386989205 hasAuthorship W4386989205A5065291663 @default.
• W4386989205 hasAuthorship W4386989205A5068857043 @default.
• W4386989205 hasBestOaLocation W43869892051 @default.
• W4386989205 hasConcept C126322002 @default.
• W4386989205 hasConcept C177713679 @default.
• W4386989205 hasConcept C187212893 @default.
• W4386989205 hasConcept C2776376669 @default.
• W4386989205 hasConcept C2777091541 @default.
• W4386989205 hasConcept C2778376644 @default.
• W4386989205 hasConcept C2778644256 @default.
• W4386989205 hasConcept C2779234561 @default.
• W4386989205 hasConcept C534529494 @default.
• W4386989205 hasConcept C54355233 @default.
• W4386989205 hasConcept C71924100 @default.
• W4386989205 hasConcept C86803240 @default.
• W4386989205 hasConceptScore W4386989205C126322002 @default.
• W4386989205 hasConceptScore W4386989205C177713679 @default.
• W4386989205 hasConceptScore W4386989205C187212893 @default.
• W4386989205 hasConceptScore W4386989205C2776376669 @default.
• W4386989205 hasConceptScore W4386989205C2777091541 @default.
• W4386989205 hasConceptScore W4386989205C2778376644 @default.
• W4386989205 hasConceptScore W4386989205C2778644256 @default.
• W4386989205 hasConceptScore W4386989205C2779234561 @default.
• W4386989205 hasConceptScore W4386989205C534529494 @default.
• W4386989205 hasConceptScore W4386989205C54355233 @default.
• W4386989205 hasConceptScore W4386989205C71924100 @default.
• W4386989205 hasConceptScore W4386989205C86803240 @default.
• W4386989205 hasIssue "Supplement_1" @default.
• W4386989205 hasLocation W43869892051 @default.
• W4386989205 hasOpenAccess W4386989205 @default.
• W4386989205 hasPrimaryLocation W43869892051 @default.
• W4386989205 hasRelatedWork W1589200039 @default.
• W4386989205 hasRelatedWork W2001093521 @default.
• W4386989205 hasRelatedWork W2056220675 @default.
• W4386989205 hasRelatedWork W2093453383 @default.
• W4386989205 hasRelatedWork W2374848512 @default.
• W4386989205 hasRelatedWork W2573237218 @default.
• W4386989205 hasRelatedWork W2585380485 @default.
• W4386989205 hasRelatedWork W2930179225 @default.
• W4386989205 hasRelatedWork W4232065395 @default.
• W4386989205 hasRelatedWork W4307580637 @default.
• W4386989205 hasVolume "28" @default.
• W4386989205 isParatext "false" @default.
• W4386989205 isRetracted "false" @default.
• W4386989205 workType "article" @default.